ClinicalTrials.Veeva

Menu
T

Tandem Clinical Research | Marrero, LA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Relamorelin
LY3298176
Tirzepatide
Guselkumab
Ozanimod
Cenicriviroc
RTA 901
ABX464
OTO-313
Survodutide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

47 of 103 total trials

A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

This is a randomized, double-blind, placebo-controlled, phase 1b study designed to evaluate safety, tolerability, PK, and preliminary efficacy of APL...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: APL-1401

This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and pharmacokinetics (P...

Enrolling
Diabetic Peripheral Neuropathic Pain
Drug: RTA 901
Drug: RTA 901-Matching Placebo

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Procedure: Liver Biopsy
Drug: MGL-3196

This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have metabolic...

Enrolling
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Drug: Placebo
Drug: ALN-HSD

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to sever...

Enrolling
Lupus Erythematosus, Systemic
Drug: Cenerimod
Drug: Placebo

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Active, not recruiting
Depressive Disorder, Major
Drug: Aticaprant

This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic ste...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Drug: Placebo
Drug: Efimosfermin

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adult Eosinophilic Esophagitis patients.

Active, not recruiting
Eosinophilic Esophagitis
Biological: barzolvolimab
Drug: Matching Placebo

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting
Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Active, not recruiting
Crohn Disease
Drug: Guselkumab Dose 3
Drug: Placebo

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severe...

Active, not recruiting
Colitis, Ulcerative
Drug: Placebo
Drug: JNJ-77242113

The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in p...

Active, not recruiting
Type 2 Diabetes
Drug: Orforglipron
Drug: Dapagliflozin

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Enrolling
Alzheimer's Disease
Drug: Placebo
Drug: Remternetug

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of gus...

Active, not recruiting
Crohn's Disease
Drug: Ustekinumab
Drug: Guselkumab Dose 3

The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than t...

Active, not recruiting
Obesity
Drug: Mibavademab-Placebo
Drug: Tirzepatide-Placebo

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Active, not recruiting
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling
Diabetic Gastroparesis
Drug: Placebo
Drug: CIN-102 Dose 15mg or 10mg
Locations recently updated

Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Al...

Enrolling
Alzheimer Disease
Dementia
Drug: MK-1167
Drug: Placebo

This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (...

Active, not recruiting
Obesity
Drug: Matching Placebo-Trevogrumab
Drug: Matching Placebo-Garetosmab

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Lilly logo
Regeneron Pharmaceuticals logo
Allergan logo
Boehringer Ingelheim logo
Celgene logo
Otonomy logo
Roche logo
A
AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems